|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2006-3-10
|
|
pubmed:abstractText |
A series of competitive, reversible cathepsin S (CatS) inhibitors was investigated. An earlier disclosure detailed the discovery of the 4-(2-keto-1-benzimidazolinyl)-piperidin-1-yl moiety as an effective replacement for the 4-arylpiperazin-1-yl group found in our screening hit. Continued investigation into replacements for the 4-aryl piperazine resulted in the identification of potentially useful CatS inhibitors with enzymatic and cellular activity similar to that of JNJ 10329670 as disclosed in a previous publication.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:ButlerChristopher RCR,
pubmed-author:EdwardsJames PJP,
pubmed-author:GriceCheryl ACA,
pubmed-author:GuYinY,
pubmed-author:GustinDarin JDJ,
pubmed-author:JiangWenW,
pubmed-author:KarlssonLarsL,
pubmed-author:KhatuyaHaripadaH,
pubmed-author:SehonClark ACA,
pubmed-author:SunSiquanS,
pubmed-author:TaysKevinK,
pubmed-author:ThurmondRobin LRL,
pubmed-author:WeiJianmeiJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2209-12
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
The SAR of 4-substituted (6,6-bicyclic) piperidine cathepsin S inhibitors.
|
|
pubmed:affiliation |
Johnson and Johnson Pharmaceutical Research and Development, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA. cgrice@prdus.jnj.com
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
